SOMAÍ Pharmaceuticals Expands Its Most Comprehensive Medicinal Cannabis Portfolio With Mint Oral Solutions Launch

SOMAÍ Pharmaceuticals is proud to announce the Mint Oral Solutions product line launch in Australia, Germany, and the UK.

SOMAÍ Pharmaceuticals ("SOMAÍ"), a fully vertically integrated Multi-Country Operator (MCO) in the global medical cannabis markets, is proud to announce the Mint Oral Solutions product line launch in Australia, Germany, and the UK.SOMAÍ constantly focuses on patients' needs and preferences to produce innovative, improved performance and tasting products. The new line includes single-strain oils infused with peppermint terpene mixes in various dosage forms, from CBD-dominant to balanced and high-THC. The mint line is the first introduction to improve patients' compliance and treatment adherence, combining purified extracts and a subtle aromatic mint taste."Cannabis patients prioritize the products' performance, smell, and taste," said Michael Sassano, the founder and interim CEO of SOMAI Pharmaceuticals. "So as we prioritize improving patient experience, mint is an excellent starting experience as a popular blend with calming and therapeutic effects, as well as a pleasant subtle taste."Earlier this year, SOMAÍ launched its first improved-tasting Oral Solutions Essentials product line. October will showcase the next-gen Origins lines and Senses lines of oral extracts as well as inhalation full lines. With over 100 extracted products in and out of stability, including inhalation oils, oral sprays, soft gel capsules, and oral gums with various terpene mixes, more advanced formulations will soon be released on the global markets. Currently, the company is present in the Australian, German, and UK markets and will soon launch in six other countries in Q3/4 2024.